


Today's Fringe
Is Tomorrow's
Mainstream



Futuristic visions of flight from the 1800s

TEN MEGATRENDS

- 1. Digital health/Al
- 2. OMICS
- 3. Molecular Diagnostics and targeted treatment
- 4. Nanomedicine
- 5. Cell/gene therapy
- 6. Stemcells & regenerative medicine
- 7. Bioprinting
- 8. Imaging: Augmented/virtual/realview/molecular
- 9. Robotics
- 10. Sensors & monitors








Hype Cycle Of The Top 50 Emerging Digital Health Trends In 2021





Top 10 AI Applications



Robot-Assisted Surgery"

\$40B



Virtual Nursing Assistants

\$20B



Administrative Workflow Assistance

\$18B



Fraud Detection

\$17B



Dosage Error Reduction

\$16B



Connected Machines

\$14B



Clinical Trial Participant Identifier

\$13B



Preliminary Diagnosis

\$5B




Automated Image Diagnosis

\$3B




Cybersecurity


\$2B




ARTIFICIAL INTELLIGENCE & DECISION SUPPORT ENHANCED EMR








OMICS TO PATHOGENESIS TO TREAT







MOLECULAR DIAGNOSTIC & TARGETED TREATMENT




MOLECULAR DIAGNOSIS / LIQUID BIOPSY







THE PROSPECTS








SYNTHESIS OF BIOMOLECULES






NANOMEDICINE




Nanomaterials, Biological Devices, Nanoelectronic Biosensors, Nanobots


- Drug Delivery
- Teranostics
- Nanobiosensors
- Nanobots





TARGETED DRUG DELIVERY

- Lyposomes
- Polymeres
- glycans












NANOBIOSENSORS

- Chemical, physical, biological
- Molecules (incl nuc ac)
- Closed loop









NANOBOTS

- robots that carry out a very specific function and are $\sim 50-100$ nm wide.
- They can be used very effectively for drug delivery.
- Nanoelectronics, photolithography, and new biomaterials






CELL THERAPY / GENE-EDITING




THE TECHNOLOGY



Gene Editing Business Development Deals


Date/s	Companie	s Agreement Details	# of Indications	Type	Upfront	Milestones
	AbbVie - Caribou					
2021	abbvie CARIBOU	Discover and develop allogeneic CAR-T cell therapies using Caribou's Cas12a CRISPR hybrid chRDNA	4.	Allo-CAR T	\$40M	\$300M
2021	Apellis Beam Apellis Beam	Discover novel therapies for complement-driven diseases using base editing	6	C3, Eye, Liver, Brain	\$75M	u/d
2022	Bayer - Mammoth Mammoth Bioscience	Discover and develop in vivo CRISPR-based gene editing therapies	5	Liver- targeted	\$40M	\$1B
2021	Biogen - Scribe	Discover and develop CRISPR-based genetic medicines for neurological diseases	2	ALS, Neuro	\$15M	\$400M
2015, 2019	BMS - Editas (M Bristol Myers Squibb	Develop and commercialize autologous and allogeneic T-cell therapies for cancer and autoimmune diseases	2 4 5	Alpha-Beta T cells	\$25M + \$70M	\$22M
Jul-05	CRISPR - ViaCyte	Discovery, development, commercialization of gene-edited T E stem cell therapies for diabetes	2 1 11	diabetes	\$15M	\$10M
2021	EpsilenBlo CHR@M	Chroma acquires Ensilen Rio for enigenetic edition	54.0	90	u/d	N/A
2020	life edit elevatebia	ElevateBio acquires LifeEDIT for its next-generation gene- editing platform	E# 1	54	u/d	N/A
2022	Pfizer - Beam Pfizer Beam	Discover and develop in vivo base-editing therapies	3	Liver, muscle, CNS	\$300M	\$1.05B
2021	Moderna - Metagenomi moderna metagenomi	Discover and develop next-generation in vivo gene-editing therapeutics	u/d	u/d	u/d	u/d
2021	Nkarta - CRISPR NKOrto	Develop and commercialize gene-edited cell therapies for cancer	7	CD70 tumor antigen	u/d	u/d
2015 - 2019	Novartis - Intellia	Discover and develop CRISPR-based therapies using CAR Ts and HSCs	u/d	eye disorders	\$6M + \$10M	u/d
2016, 2020	Regeneron - Intellia REGENERON Intellia	Discover and develop in vivo and ex-vivo CRISPR-based therapies for up to 10 targets including hemophilia A and B	15	Hemophilia A and B	\$75M + \$70M	\$50M
2022	rewrite Intellia	Intellia acquired Rewrite to obtain its proprietary DNA writing platform	14.5	19	\$200M	N/A
2021	Sana - Beam Sana - Beam	Sana licenses Beam's CRISPR Cas12b gene-editing technology to enable engineered cell programs	u/d	Cancer, diabetes, cardio	\$50M	u/d
2018, 2021	Vertex - Arbor Bio	Develop ex vivo cell therapies using Arbor's CRISPR gene- editing technology	u/d	T1 diabetes, SCD, BT	\$30M	\$1.2B
2015, 2019, 2021	Vertex - CRISPR VERTEX CRISPR	Discover and develop CRISPR-based therapies with amendment toward manufacturing and commercialization of CTX001 in SCD and BT; DMD, DM1	4	SCD, BT, DMD, DM1	\$105M + \$171M + \$900M	\$200M
2015, 2022	Vertex - Exonics Therapeutic		2	DMD, DM1	\$254M	Up to \$1B
2021	Vertex - Mammoth	Discovery and develop in vivo gene-editing therapies	2	u/d	\$41M	\$650M
2021	verve - Beam	Discover and develop gene-editing therapies for heart disease	e 2	HeFH, HoFH	u/d	u/d


Source: Company reports: William Blair Equity Research




STEM CELLS & REG MED

IPSC Induced Pluripotent Stem Cells










3D BIOPRINTING







BIOPRINTED TISSUES













VIRTUAL/AUGMENTED REALITY

Accuvein











VR imaging



Augmented-reality surgical navigation





MEDICAL HOLOGRAPHY



MEDICAL HOLOGRAPHY MARKET ANALYSIS

Market Taxonomy:

By Technique

- X-ray Holography
- Endoscopic Holography
- Hologram Recording
 Endoscope
- Multiplexed Holography
- Light-in-flight Holography

Major Players Operating:

- → HoloTech Switzerland AG
- ▶ Lyncee Tec
- **▶** EON Reality

- **▶** Holoxica Limited
- ▶ EchoPixel
- **▶** AUGmedics


- ▶ RealView Imaging Ltd
- ▶ Zspace
- ▶ Nanolive SA

- ▶ Phase Holographic Imaging AB
- ▶ Ovizio Imaging Systems NV/SA
- © 2021 Coherent Market Insights Pvt Ltd. All right reserved.


By Hologram Type

- Reflection Hologram
- Transmission Hologram
- Hybrid Hologram
 - o Embossed Holograms
 - o Integral Holograms
- o Holographic Interferometry
- o Multichannel Holograms
- o Computer-generated


Holograms




MOLECULAR IMAGING&TREAT TERANOSTICS **G




⁶⁸Ga-somatostatin receptors



68-Ga-PSMA and therapy with 177Lu-PSMA





ROBOTICS

- Unlimited move
- More gentle
- More accurate
- Align to
 - Imaging
 - AR
 - navigation





MEDICAL WEARABLES & SENSORS

- Wearable
- Skin
- Implant
- Closed loop

